Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
<p dir="ltr">We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favip...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , , , , , , , , , , , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513537538260992 |
|---|---|
| author | Rand A. Alattar (9538554) |
| author2 | Shiema Abdalla (9538596) Tasneem Abdallah (17380486) Rashid Kazman (17380489) Aseelah Qadmour (17380492) Tawheeda Ibrahim (17380495) Bassem Alhariri (9538578) Shahd H. Shaar (9538560) Abeer Bajwa (17380498) Abeir Alimam (17380501) Rabia Qazi (17380504) Fatma Ben Abid (17269003) Joanne Daghfal (9538551) Ali Eldeeb (17380507) Kinda Shukri (17380510) Ahmed Elsayed (5055611) Fatima Rustom (12501662) Musaed Alsamawi (14778031) Alaaeldin Abdelmajid (12535542) Miguel A.P. Basulto (17380513) Armando A.R. Cobian (17380516) Mohamed Abukhattab (17380519) Abdullatif Alkhal (9538626) Muna A. Almaslamani (9538548) Ali S. Omrani (9590116) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Rand A. Alattar (9538554) Shiema Abdalla (9538596) Tasneem Abdallah (17380486) Rashid Kazman (17380489) Aseelah Qadmour (17380492) Tawheeda Ibrahim (17380495) Bassem Alhariri (9538578) Shahd H. Shaar (9538560) Abeer Bajwa (17380498) Abeir Alimam (17380501) Rabia Qazi (17380504) Fatma Ben Abid (17269003) Joanne Daghfal (9538551) Ali Eldeeb (17380507) Kinda Shukri (17380510) Ahmed Elsayed (5055611) Fatima Rustom (12501662) Musaed Alsamawi (14778031) Alaaeldin Abdelmajid (12535542) Miguel A.P. Basulto (17380513) Armando A.R. Cobian (17380516) Mohamed Abukhattab (17380519) Abdullatif Alkhal (9538626) Muna A. Almaslamani (9538548) Ali S. Omrani (9590116) |
| author_role | author |
| dc.creator.none.fl_str_mv | Rand A. Alattar (9538554) Shiema Abdalla (9538596) Tasneem Abdallah (17380486) Rashid Kazman (17380489) Aseelah Qadmour (17380492) Tawheeda Ibrahim (17380495) Bassem Alhariri (9538578) Shahd H. Shaar (9538560) Abeer Bajwa (17380498) Abeir Alimam (17380501) Rabia Qazi (17380504) Fatma Ben Abid (17269003) Joanne Daghfal (9538551) Ali Eldeeb (17380507) Kinda Shukri (17380510) Ahmed Elsayed (5055611) Fatima Rustom (12501662) Musaed Alsamawi (14778031) Alaaeldin Abdelmajid (12535542) Miguel A.P. Basulto (17380513) Armando A.R. Cobian (17380516) Mohamed Abukhattab (17380519) Abdullatif Alkhal (9538626) Muna A. Almaslamani (9538548) Ali S. Omrani (9590116) |
| dc.date.none.fl_str_mv | 2022-10-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.jiph.2022.08.011 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Favipiravir_for_the_treatment_of_coronavirus_disease_2019_pneumonia_a_propensity_score-matched_cohort_study/24551473 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Health sciences Public health COVID-19 SARS-CoV-2 Pneumonia Favipiravir Antiviral therapy |
| dc.title.none.fl_str_mv | Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. The unmatched cohort included 1493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001). Adverse events were common in both groups, but the 93.9% were Grades 1–3. Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Infection and Public Health<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.jiph.2022.08.011" target="_blank">https://dx.doi.org/10.1016/j.jiph.2022.08.011</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_45bf54b67a9ebc4bb2172cb6d27f6c14 |
| identifier_str_mv | 10.1016/j.jiph.2022.08.011 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/24551473 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort studyRand A. Alattar (9538554)Shiema Abdalla (9538596)Tasneem Abdallah (17380486)Rashid Kazman (17380489)Aseelah Qadmour (17380492)Tawheeda Ibrahim (17380495)Bassem Alhariri (9538578)Shahd H. Shaar (9538560)Abeer Bajwa (17380498)Abeir Alimam (17380501)Rabia Qazi (17380504)Fatma Ben Abid (17269003)Joanne Daghfal (9538551)Ali Eldeeb (17380507)Kinda Shukri (17380510)Ahmed Elsayed (5055611)Fatima Rustom (12501662)Musaed Alsamawi (14778031)Alaaeldin Abdelmajid (12535542)Miguel A.P. Basulto (17380513)Armando A.R. Cobian (17380516)Mohamed Abukhattab (17380519)Abdullatif Alkhal (9538626)Muna A. Almaslamani (9538548)Ali S. Omrani (9590116)Biomedical and clinical sciencesCardiovascular medicine and haematologyHealth sciencesPublic healthCOVID-19SARS-CoV-2PneumoniaFavipiravirAntiviral therapy<p dir="ltr">We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. The unmatched cohort included 1493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001). Adverse events were common in both groups, but the 93.9% were Grades 1–3. Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Infection and Public Health<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.jiph.2022.08.011" target="_blank">https://dx.doi.org/10.1016/j.jiph.2022.08.011</a></p>2022-10-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.jiph.2022.08.011https://figshare.com/articles/journal_contribution/Favipiravir_for_the_treatment_of_coronavirus_disease_2019_pneumonia_a_propensity_score-matched_cohort_study/24551473CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/245514732022-10-01T00:00:00Z |
| spellingShingle | Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study Rand A. Alattar (9538554) Biomedical and clinical sciences Cardiovascular medicine and haematology Health sciences Public health COVID-19 SARS-CoV-2 Pneumonia Favipiravir Antiviral therapy |
| status_str | publishedVersion |
| title | Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study |
| title_full | Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study |
| title_fullStr | Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study |
| title_full_unstemmed | Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study |
| title_short | Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study |
| title_sort | Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Health sciences Public health COVID-19 SARS-CoV-2 Pneumonia Favipiravir Antiviral therapy |